Pacira BioSciences (NASDAQ:PCRX) Given New $55.00 Price Target at Truist Financial

Pacira BioSciences (NASDAQ:PCRX – Free Report) had its target price decreased by Truist Financial from $60.00 to $55.00 in a research note published on Thursday morning, MarketBeat.com reports. Truist Financial currently has a buy rating on the stock. Several other brokerages also recently commented on PCRX. HC Wainwright lowered their price target on Pacira BioSciences […]

Related Keywords

United States ,Piper Sandler ,Pacira Biosciences ,Lauren Bullaro Riker ,Roy Winston ,Group Wealth Management ,Needham Company ,Pacira Biosciences Inc ,Us Capital Wealth Advisors ,R Capital Management Inc ,Financial Freedom ,Free Report ,Truist Financial ,Moderate Buy ,Get Free Report ,Bullaro Riker ,Wealth Management ,Forest Capital Management ,Wealth Advisors ,Pacira Biosciences Daily ,Nasdaq Pcrx ,Pcrx ,Medical ,69512710 ,Lower Price Target ,Truist Financial Co ,